Oncology
Pluvicto Moves Earlier in PSMA-Positive Prostate Cancer
The FDA has moved lutetium Lu-177 vipivotide tetraxetan into PSMA-positive metastatic hormone-sensitive prostate cancer when combined with an androgen receptor pathway inhibitor.
Dr. Abu Bakar · August 22, 2026 · 7 min